Toronto, Ontario–(Newsfile Corp. – December 28, 2020) – Psyched Wellness Ltd.(CSE: PSYC) (OTCQB: DCNPF) (FSE: 5U9) (formerly Duncan Park Holdings Corporation) (the “Company” or “Psyched“) a life sciences company focused on the production and distribution of artisanal functional and psychedelic mushrooms, is pleased to announce that it has commenced research on Muscimol for various ailments, with a focus on mental health issues.
The research is led by Psyched Wellness’s board member, Prof. David Nutt. Prof. Nutt is a psychiatrist at the Edmond J. Safra Professor of Neuropsychopharmacology in the Division of Brain Science, Dept. of Medicine, Hammersmith Hospital, Imperial College London and is the Chair of the Scientific Advisory Board for COMPASS Pathways.
The purpose of the research is to gather all the scientific papers surrounding Muscimol and its various ailments, in order to support using Muscimol for mental health issues.
“It is truly inspiring to work close with Prof. Nutt, and I am curious to read this substantial research,” said David Shisel, COO of the Company. “This research is the first step towards the pharmaceutical path, and will give our fast-growing company a road map to begin the first clinical trials on our extraction.”
For further information, please contact:
Sign up for MORE news updates !
This article is written and published by The Cannabis Stock
Disclaimer : The Cannabis Stock wants to promote the cannabis market with the best articles and news on the market. The Cannabis Stock does not recommend selling or buying any of the company mentioned and is not responsible for any losses that may result. The Cannabis Stock are engaged in the business of marketing and advertising companies
The Cannabis Stock and its employees may from time to time own shares of the companies named in the articles. All the facts reported by the cannabis stock are information that comes directly from the companies, from their website or on Sedar and are only published as information.